Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

Argo Biopharma Receives IND Approval for Phase II Clinical Trial of Promising siRNA-PEG-IFNα Combination Therapy in Chronic Hepatitis B

Argo Biopharma Announces First Subject Dosed in Phase I Clinical Trial of an Investigational siRNA Therapy BW-40202 Targeting Complement Factor B

Argo Biopharma’s Novel siRNA Therapeutic BW-20507 Granted Breakthrough Therapy Designation in China for Chronic Hepatitis B Virus Infection

Argo Biopharma Announces Phase 2 Advancement and Milestone Payment for siRNA Molecule BW-00163

Argo Biopharma to Present Promising Phase 1/2a Results of siRNA Therapeutic BW-20507 for Chronic Hepatitis B at EASL Congress 2025 (Late-Breaker)